About the Consortium
Recent advances in techniques for the isolation and analysis of single-cells are now enabling researchers to explore cellular heterogeneity in normal and diseased tissues at an unprecedented scale:
- Gawad, C., Koh, W. and Quake, S.R. (2016) Single-cell genome sequencing: current state of the science. Nature reviews. Genetics, in press.
- Wills, Q.F. and Mead, A.J. (2015) Application of single-cell genomics in cancer: promise and challenges. Human molecular genetics, 24, R74-84.
- Wills, Q.F., Higgs, D.R. and Mead, A.J. (2015) Studying epigenomics in single cells: what is feasible and what can we learn? Epigenomics, 7, 1231-1234.
In July 2014 Professors Doug Higgs and Kay Davies were awarded a grant of £5M via the UK Clinical Research Capabilities and Technologies Initiative (CRI) to establish the Oxford Single Cell Biology Consortium (OSCBC). The aim of the OSCBC is to rapidly apply advances in single-cell technologies to improve the diagnosis, stratification and treatment of human diseases. The OSCBC includes over 30 interactive research groups across the Oxford Biomedical Institutes and Science Departments working on a wide range of different areas.
The OSCBC also houses a number of state of the art technology platforms housed in two single-cell facilities based at the Weatherall Institute of Molecular Medicine (WIMM) and the Oxford Genomics Centre at the Wellcome Trust Centre for Human Genetics. (WTCHG).
OSCBC researchers meet regularly to share data and research ideas and the OSCBC steering group meets regularly to oversee current activities and new developments in the Consortium.
Steering group members:
- Dr Neil Ashley, WIMM
- Dr Rory Bowden, WTCHG
- Professor Enzo Cerundolo, WIMM
- Professor Doug Higgs (Chair), WIMM
- Professor Chris Holmes, WTCHG
- Dr Stella Keeble, WIMM
- Professor Rob Klose, Department of Biochemistry
- Dr Adam Mead, WIMM
- Dr Conrad Nieduszynski, Dunn School
- Dr Quin Wills, WTCHG